Arnold Dirk
Department of Oncology and Hematology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Cancer Treat Rev. 2008;34 Suppl 2:S12-6. doi: 10.1016/S0305-7372(08)70004-5.
A 62-year-old male presents with colon cancer that has metastasized to both lobes of the liver. Resection was performed; chemotherapy initially consisted of combination treatment with FOLFIRI or XELIRI plus bevacizumab, with the possibility of changing treatment to either FU/LV or capecitabine, combined with bevacizumab. Although reported data would allow the consideration of a strategy of sequential treatment in this patient, the consulting oncologists treating him have acknowledged the benefit of a strategy employing "inductive" combination chemotherapy plus monoclonal antibodies. Combination chemotherapy offers the potential for longer treatment holidays than is possible with sequential therapy. One of the enduring concepts informing treatment decisions for mCRC is that patients who receive the three mainstays of drug treatment fluorouracil, irinotecan, and oxaliplatin fare better than those who do not.
一名62岁男性被诊断患有已转移至肝脏两叶的结肠癌。已进行了手术切除；化疗最初采用FOLFIRI或XELIRI联合贝伐单抗的联合治疗，也有可能将治疗方案改为氟尿嘧啶/亚叶酸钙或卡培他滨联合贝伐单抗。尽管已报道的数据支持考虑对该患者采用序贯治疗策略，但治疗他的会诊肿瘤学家认可采用“诱导性”联合化疗加单克隆抗体策略的益处。联合化疗比序贯治疗有可能提供更长的治疗间歇期。指导转移性结直肠癌治疗决策的一个持久观念是，接受氟尿嘧啶、伊立替康和奥沙利铂这三种主要药物治疗的患者比未接受这些治疗的患者预后更好。
